[1]张家豪,孙超峰.伊伐布雷定治疗冠心病合并慢性阻塞性肺病心力衰竭临床疗效研究[J].陕西医学杂志,2019,(2):256-258，封3.
　ZHANG Jiahao,SUN Chaofeng..Clinical effect of Ivabradine on Coronary heart disease combined with chronic obstructive pulmonary disease.[J].,2019,(2):256-258，封3.
点击复制

伊伐布雷定治疗冠心病合并慢性阻塞性肺病心力衰竭临床疗效研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2019年2期
页码:
256-258，封3
栏目:
药物与临床
出版日期:
2020-02-05

文章信息/Info

Title:
Clinical effect of Ivabradine on Coronary heart disease combined  with chronic obstructive pulmonary disease.
文章编号:
DOI: 10.3969/j.issn.10007377.2019.02.032
作者:
张家豪; 孙超峰
西安交通大学第一附属医院心血管内科（西安710061）
Author(s):
ZHANG Jiahao; SUN Chaofeng.
Department of Cardiovascular,First Affiliated Hospital of Xi’an Jiaotong University (Xi’an 710061）
关键词:
冠状动脉疾病; 肺疾病; 慢性阻塞性; 药物疗法; 依伐布雷定; 利钠钛; 脑; 代谢
Keywords:
Key words Coronary disease; Pulmonary disease; chronic obstructive; Drug therapy; Ivabradine; Natriurtic peptide; brain; Metabolism
分类号:
R737.31
文献标志码:
A
摘要:
摘 要 目的：探讨伊伐布雷定片对冠心病合并慢性阻塞性肺病（COPD）心力衰竭患者的临床疗效及安全性。方法：收集冠心病合并COPD患者60例，随机分入对照组和治疗组各30例。两组均予标准化抗心力衰竭及必要时抗感染、平喘、祛痰等治疗，同时治疗组联合应用伊伐布雷定治疗。比较分析对照组与治疗组用药前后的PaO2、PaCO2、SaO2、心率、左心室射血分数(LVEF)、N末端脑钠肽原(NTproBNP)与６min步行距离（６ＭＷＤ）；记录治疗期间的不良反应。 结果:与对照组相比，治疗组患者的PaO2、SaO2、LVEF明显升高，PaCO2、心率、血浆NTproBNP明显降低，６ＭＷＤ与治疗前比较差异均有统计学意义。结论:伊伐布雷定治疗冠心病合并COPD心力衰竭患者安全有效，可明显降低血浆生物标志物水平。
Abstract:
Abstract Objective: To explore the clinical efficacy and safety of Ivabradine on the coronary heart disease (CHD) patients combined Chronic obstructive pulmonary disease (COPD) and heart failure. Methods: The patients(n=60) who diagnosed coronary heart disease (CHD) with COPD by physician internist were randomly divided into control group(30) and treatment group(30), both groups’ patients were accepted the standardized treatment of anti heart failure and the treatment of antiinfection, and relieving asthma, eliminating phlegm when necessary, in the meantime, patients in treatment group were treated with Ivabradine. The PaO2, PaCO2, SaO2, heart rate, left ventricular ejection fraction (LVEF), Nterminal brain natriuretic peptide (NT  proBNP) with 6 min walking distance (6 MWDS) were compared in both groups before and after medication. And record adverse reactions during the treatment. Results: Compared with control group, the PaO2, SaO2, LVEF increased significantly and the PaCO2, heart rate, blood plasma NTproBNP significantly decreased in the patients of treatment group.The 6 MWDS compared with before treatment differences were statistically significant. Conclusion: The Ivabradine is safe and effective to the the coronary heart disease (CHD) patients combined chronic obstructive pulmonary disease (COPD) and heart failure,Ivabradine can reduce the level of serum biomarkers obviously.

参考文献/References:

\[1\] Di Franco A，Sarullo FM，Salerno Y，et al．Betablockers and ivabradine in chronic heart failure：from clinical trials to clinical practice\[J\]．American Journal of Cardiovascular Drugs,2014，14(2)：101110．
\[2\] 王庆旭,周致远,李德才,等 . 米力农对老年心力衰竭心功能及血清hsCRP、TNFα、IL6水平的影响\[J\]. 陕西医学杂志,2017， 46(5): 602604.
\[3\] 刘纪红，林海叶，崔 悦，等 . 基于离子通道的心力衰竭病理分析仿真研究\[J\]. 东北大学学报：自然科学版，2013，34(11):1 5331 536.
\[4\] Majewski S，Slomka S，ZielinskaWyderkiewicz E，et al．Heart ratelowering efficacy and respiratory ,safety of ivabradine in patients with obstructive airway disease：a randomized，double blind，placebocontrolled，crossover study\[J\]．Am J Cardiovasc Drugs，2012，12(3)：179188．
\[5\] Piehler P，Pichler Cetin E，Vertesich M，et al．Ivabradine versus metoprolol for heart rate reduction before coronary computed tomography angiography\[J\]．Am J Cardiol，2012，109(2)：169173．
\[6\] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014\[J\].中华心血管病杂志,2014,42(2):98122.
\[7\] Majewski S, Slomka S, ZielinskaWyderkiewicz E, et al. Heart ratelowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, placebocontrolled, crossover study\[J\].Am J Cardiovasc Drugs,2012,12(3):179188.
\[8\] 黄国鹏,安 素. N末端B型利钠肽原对老年心衰临床应用价值的研究\[J\].中国循环杂志, 2014, 29: 698701.
\[9\] Savarese G,Trimarco B,Dellegrottaglie S,et al.Natriuretic peptideguided therapy in chronic heart failure: a metaanalysis of 2,686 patients in 12 randomized trials\[J\].PLoS One,2013,8(3):e58287.〖ZK)〗
\[10\] Swedberg K, Komajda M, Bohm M, et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of betablocker dose? Findings from the SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study\[J\]. J Am Coll Cardiol, 2012, 59: 19381945.
\[11\] Ates I, Yavuz AH, Doru M, et al. Effects of ivabradine on 6minute walk test and quality of life in patients with previously implanted CRTD\[J\]. J Investig Med, 2013, 61: 10131017.

相似文献/References:

[1]麻友键,李志勇.心脏超声在定量评估冠心病介入治疗前后心肌功能中的应用[J].陕西医学杂志,2016,(10):1357.
[2]魏建全,白嵘.糖皮质激素与抗生素配伍治疗老年慢性阻塞性肺疾病60例[J].陕西医学杂志,2016,(09):1125.
[3]李学玲,张春峰.不同剂量舒利迭治疗老年中重度稳定期慢性阻塞性肺疾病疗效观察[J].陕西医学杂志,2016,(09):1224.

更新日期/Last Update: 2019-03-13